Clinical Trial Update: Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

An early-phase study evaluating IMX-110 in combination with tislelizumab in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• IMX-110
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Immix Biopharma, Inc. | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN